The authors declare that they have no competing interests.
TO conceived and designed the study. OH collected previous reports of Kampo medicine regarding cancer-related palliative care and reviewed them. He categorized its usage into ten types and elaborated on them. AK had the responsibility for the final approval of the article. Both authors read and approved the final manuscript.
Kampo medicines are currently manufactured under strict quality controls. The Ministry of Health, Labour and Welfare of Japan has approved 148 Kampo formulas. There is increasing evidence for the efficacy of Kampo medicines, and some are used clinically for palliative care in Japan. The specific aim of this review is to evaluate the clinical use of Kampo medicines in palliative care in the treatment of cancer. The conclusions are as follows: Juzentaihoto inhibits the progression of liver tumors in a dose-dependent manner and contributes to long-term survival. Hochuekkito has clinical effects on cachexia for genitourinary cancer and improves the QOL and immunological status of weak patients, such as postoperative patients. Daikenchuto increases intestinal motility and decreases the postoperative symptoms of patients with total gastrectomy with jejunal pouch interposition, suppresses postoperative inflammation following surgery for colorectal cancer, and controls radiation-induced enteritis. Rikkunshito contributes to the amelioration of anorectic conditions in cancer cachexia-anorexia syndrome. Goshajinkigan and Shakuyakukanzoto reduce the neurotoxicity of patients with colorectal cancer who undergo oxaliplatin and FOLFOX (5-fluorouracil/folinic acid plus oxaliplatin) therapy. Hangeshashinto has the effect of preventing and alleviating diarrhea induced by CPT-11(irinotecan) and combination therapy with S-1/CPT-11. O’rengedokuto significantly improves mucositis caused by anticancer agents.
Iwase S, Yamaguchi T, Miyaji T, Terawaki K, Inui A, Uezono Y: The clinical use of Kampo medicines (traditional Japanese herbal treatments) for controlling cancer patients’ symptoms in Japan. A national cross-sectional survey. BMC Complement Altern Med. 2012, 12: 222-10.1186/1472-6882-12-222. PubMedCentralCrossRefPubMed
Ohnishi Y, Fujii H, Hayakawa Y, Sakukawa R, Yamaura T, Sakamoto T, Tsukada K, Fujimaki M, Nunome S, Komatsu Y, Saiki I: Oral administration of a Kampo (Japanese herbal) medicine Juzen-taiho-to inhibits liver metastasis of colon 26-L5 carcinoma cells. Jpn J Cancer Res. 1998, 89 (2): 206-213. 10.1111/j.1349-7006.1998.tb00550.x. CrossRefPubMed
Kuroiwa A, Liou S, Yan H, Eshita A, Naitoh S, Nagayama A: Effect of a traditional Japanese herbal medicine, Hochu-ekki-to (Bu-Zhong-Yi-Qi Tang), on immunity in elderly persons. Int Immunopharmacol. 2012, 4 (2): 317-324. CrossRef
Kuroda M, Kotake T, Sonoda T, Maekawa M, Okajima E, Okawa T, Ikoma F, Kurita T, Nakamura T, Itatani H: The clinical evaluation of hochuekkito for symptoms of malignant neoplasm patients. [Article in Japanese]. Hinyokika Kiyo. 1985, 31 (1): 173-177. PubMed
Satoh N, Sakai S, Kogure T, Tahara E, Origasa H, Shimada Y, Kohoda K, Okubo T, Terasawa K: A randomized double blind placebo-controlled clinical trial of Hochuekkito, a traditional herbal medicine, in the treatment of elderly patients with weakness N of one and responder restricted design. Phytomedicine. 2005, 12 (8): 549-554. 10.1016/j.phymed.2004.06.014. CrossRefPubMed
Yoshikawa K, Shimada M, Nishioka M, Kurita N, Iwata T, Morimoto S, Miyatani T, Komatsu M, Kashihara H, Mikami C: The effects of the Kampo medicine (Japanese herbal medicine) “Daikenchuto” on the surgical inflammatory response following laparoscopic colorectal resection. Surg Today. 2012, 42 (7): 646-651. 10.1007/s00595-011-0094-4. CrossRefPubMed
Kaku H, Kumagai S, Onoue H, Takada A, Shoji T, Miura F, Yoshizaki A, Sato S, Kigawa J, Arai T, Tsunoda S, Tominaga E, Aoki D, Sugiyama T: Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel/carboplatin therapy: a multicenter collaborative study. Exp Ther Med. 2012, 3 (1): 60-65. PubMedCentralPubMed
Kono T, Mamiya N, Chisato N, Ebisawa Y, Yamazaki H, Watari J, Yamamoto Y, Suzuki S, Asama T, Kamiya K: Efficacy of goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer. Evid Based Complement Alternat Med. 2011, 2011: 418481- PubMedCentralCrossRefPubMed
Hosokawa A, Ogawa K, Ando T, Suzuki N, Ueda A, Kajiura S, Kobayashi Y, Tsukioka Y, Horikawa N, Yabushita K, Fukuoka J, Sugiyama T: Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study. Anticancer Res. 2012, 32 (7): 2545-2550. PubMed
Kobayashi K: Chemotherapy-induced diarrhea [Article in Japanese]. Gan To Kagaku Ryoho. 2003, 30 (6): 765-771. PubMed
Mori K, Kondo T, Kamiyama Y, Kano Y, Tominaga K: Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 2003, 51 (5): 403-406. PubMed
Hibi S, Ina K, Furuta R, Kataoka T, Kojima S, Kawai M: Clinical effects of Hange-shashin-to on combination therapy of S-1/irinotecan against the for patients with metastatic gastric and colorectal cancer [Article in Japanese]. Gan To Kagaku Ryoho. 2009, 36 (9): 1485-1488. PubMed
Yuki F, Kawaguchi T, Hazemoto K, Asou N: Preventive effects of oren-gedoku-to on mucositis caused by anticancer agents in patients with acute leukemia [Article in Japanese]. Gan To Kagaku Ryoho. 2003, 30 (9): 1303-1307. PubMed
- Kampo medicine for palliative care in Japan
- BioMed Central
Neu in den Fachgebieten Neurologie und Psychiatrie
Meistgelesene Bücher in der Neurologie & Psychiatrie